Mechanism of action
Haloperidol is a butyrophenone derivative that acts primarily as a dopamine D2 receptor antagonist in the central nervous system. Its antipsychotic effects result from blocking D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions.
The drug has high affinity for D2 receptors but minimal anticholinergic, antihistaminic, or alpha-adrenergic blocking activity, which distinguishes it from low-potency typical antipsychotics like chlorpromazine. This receptor profile explains both its efficacy and its characteristic adverse effect profile.
Receptor binding profile
- Strong D2 antagonism: Primary therapeutic and adverse effect mechanism
- Minimal muscarinic blockade: Low anticholinergic side effects
- Minimal histamine H1 blockade: Less sedation than low-potency agents
- Minimal alpha-1 blockade: Less orthostatic hypotension
Blockade of D2 receptors in the nigrostriatal pathway produces extrapyramidal symptoms. Blockade in the tuberoinfundibular pathway causes hyperprolactinemia by removing dopamine's tonic inhibition of prolactin release.
- Haloperidol is a high-potency typical antipsychotic with strong D2 antagonism causing high rates of EPS.
- Acute dystonia (oculogyric crisis, torticollis) occurs within hours to days; treat with benztropine or diphenhydramine.
- Tardive dyskinesia is involuntary choreiform movements that may be irreversible even after drug discontinuation.
- Neuroleptic malignant syndrome presents with hyperthermia, lead-pipe rigidity, altered mental status, and elevated CK.
- Haloperidol blocks D2 receptors in tuberoinfundibular pathway causing hyperprolactinemia (galactorrhea, amenorrhea).
- IV haloperidol prolongs QTc interval and increases risk of torsades de pointes; requires ECG monitoring.
- High-potency antipsychotics cause more EPS but less sedation and hypotension than low-potency agents.
- Haloperidol is contraindicated in Parkinson disease as it worsens parkinsonism via nigrostriatal D2 blockade.
Indications
Haloperidol is FDA-approved for schizophrenia, Tourette syndrome, and severe behavioral problems in children. It is widely used off-label for several other psychiatric and neurological conditions:
FDA-approved indications:
- Schizophrenia: Treatment of acute and chronic psychotic symptoms
- Tourette syndrome: Suppression of motor and vocal tics
- Severe behavioral problems: In children with combative, explosive hyperexcitability
Off-label psychiatric uses:
- Acute agitation: Rapid tranquilization in emergency settings
- Delirium: Particularly in hospitalized and ICU patients (not FDA-approved for delirium)
- Mania: Acute management of manic episodes in bipolar disorder
Off-label neurological uses:
- Huntington disease: Management of chorea and behavioral disturbances
Other off-label uses:
- Nausea and vomiting: Particularly chemotherapy-induced
- Intractable hiccups: When other treatments fail
Haloperidol is available in oral, intramuscular, and intravenous formulations. A long-acting decanoate injection is used for maintenance therapy in patients requiring prolonged treatment. The choice of formulation depends on the clinical setting, urgency, and patient cooperation.
Pharmacokinetics
Absorption and distribution:
Oral haloperidol undergoes significant first-pass hepatic metabolism with bioavailability of approximately 60%. Peak plasma concentrations occur 2-6 hours after oral administration and 20 minutes after intramuscular injection. The drug is highly lipophilic and distributes widely into tissues, with a large volume of distribution. It is approximately 90% protein-bound in plasma.
Metabolism and elimination:
Haloperidol is extensively metabolized in the liver, primarily via CYP3A4 and CYP2D6 enzymes, as well as glucuronidation. The major metabolite is reduced haloperidol, which has some pharmacological activity. Metabolites are excreted in urine (40%) and feces (60%).
The elimination half-life varies by formulation:
- Oral: 12-38 hours (average ~20 hours)
- IM (short-acting): Similar to oral
- Decanoate (long-acting): 3 weeks, allowing monthly dosing
Special populations:
Elderly patients and those with hepatic impairment show reduced clearance and may require dose adjustments. Renal impairment does not significantly affect pharmacokinetics since renal excretion of unchanged drug is minimal.
Adverse effects
Haloperidol's adverse effects are primarily related to its dopamine receptor blockade in various brain pathways. As a high-potency typical antipsychotic, it causes high rates of extrapyramidal symptoms but fewer anticholinergic and sedative effects than low-potency agents.
Extrapyramidal symptoms (EPS)
EPS are the most common and clinically significant adverse effects:
- Acute dystonia: Sustained muscle contractions, torticollis, oculogyric crisis (within hours to days); treat with benztropine or diphenhydramine
- Parkinsonism: Bradykinesia, rigidity, tremor, shuffling gait (within days to weeks); treat with anticholinergics or amantadine
- Akathisia: Subjective restlessness and inability to sit still (within days to weeks); treat with beta-blockers (propranolol) or benzodiazepines
- Tardive dyskinesia: Involuntary choreiform movements of face, tongue, trunk (months to years); often irreversible, risk increases with duration of treatment
Neuroleptic malignant syndrome (NMS)
A rare but life-threatening idiosyncratic reaction characterized by:
- Hyperthermia and altered mental status
- Severe muscle rigidity ("lead-pipe rigidity")
- Autonomic instability (tachycardia, labile blood pressure, diaphoresis)
- Elevated creatine kinase and leukocytosis
Treatment requires immediate discontinuation, supportive care, dantrolene, and bromocriptine.
Cardiovascular effects
- QTc prolongation: Risk of torsades de pointes, especially with IV administration or high doses
- Hypotension (less common than with low-potency agents)
Endocrine effects
- Hyperprolactinemia: Galactorrhea, amenorrhea, sexual dysfunction, gynecomastia
- Results from D2 blockade in tuberoinfundibular pathway
Other effects
- Lowered seizure threshold
- Hepatotoxicity (rare, typically cholestatic)
- Photosensitivity
- Weight gain (less than atypical antipsychotics)
- Anticholinergic effects (minimal but can occur)
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to haloperidol or butyrophenones
- Severe central nervous system depression or comatose states
- Parkinson disease (will worsen parkinsonism)
Black Box Warnings:
- Increased mortality in elderly patients with dementia-related psychosis: Typical and atypical antipsychotics are associated with increased risk of death, mainly from cardiovascular or infectious causes; haloperidol is not approved for dementia-related psychosis
Significant warnings and precautions:
- QTc prolongation: Use with caution in patients with cardiac disease, electrolyte abnormalities (hypokalemia, hypomagnesemia), or concomitant QT-prolonging drugs; obtain baseline and periodic ECGs when using IV formulation
- Seizure risk: Lower seizure threshold; use cautiously in epilepsy
- Hepatic impairment: Dose reduction may be necessary
- Elderly patients: Increased sensitivity to adverse effects, particularly EPS and falls
- Pregnancy (Category C): Use only if benefit outweighs risk; extrapyramidal symptoms have been reported in neonates exposed in third trimester
- Breastfeeding: Excreted in breast milk; weigh risks and benefits
Conditions requiring caution:
- History of tardive dyskinesia or severe EPS
- Cardiovascular disease, especially arrhythmias
- Thyrotoxicosis (may precipitate severe neurotoxicity)
- Concurrent alcohol or CNS depressant use
Drug interactions
Haloperidol has numerous clinically significant drug interactions due to its metabolism and pharmacodynamic effects.
Pharmacodynamic interactions
QTc-prolonging drugs (additive risk):
- Antiarrhythmics (amiodarone, sotalol, quinidine)
- Macrolide antibiotics (erythromycin, clarithromycin)
- Fluoroquinolones (moxifloxacin)
- Other antipsychotics
- Methadone
CNS depressants (additive sedation):
- Benzodiazepines, opioids, alcohol, barbiturates, general anesthetics
Dopaminergic drugs (antagonistic effects):
- Levodopa and dopamine agonists (haloperidol opposes their effects)
Anticholinergic drugs:
- May reduce antipsychotic efficacy and increase anticholinergic side effects
- May mask early signs of tardive dyskinesia
Pharmacokinetic interactions
CYP3A4 inhibitors (increase haloperidol levels):
- Ketoconazole, itraconazole
- Ritonavir and other protease inhibitors
- Grapefruit juice
CYP3A4 inducers (decrease haloperidol levels):
- Carbamazepine, phenytoin, phenobarbital
- Rifampin
- St. John's wort
CYP2D6 inhibitors (may increase levels):
- Fluoxetine, paroxetine, bupropion, quinidine
Dose adjustments may be necessary when these interacting drugs are added or discontinued. Monitor for efficacy and toxicity when drug combinations change.
Clinical pearls
- High-potency vs. low-potency: Remember the trade-off: high-potency agents like haloperidol cause more EPS but less sedation, hypotension, and anticholinergic effects than low-potency typical antipsychotics
- Acute agitation: Haloperidol IM is commonly used for rapid tranquilization but carries higher QTc risk than oral; consider combining with benzodiazepines (lorazepam) for faster onset and lower total antipsychotic dose
- Decanoate for non-adherence: Long-acting haloperidol decanoate given every 4 weeks is an option for patients with poor medication adherence in schizophrenia
- EPS prophylaxis: Routine prophylactic anticholinergics (benztropine) are sometimes given with haloperidol to prevent acute dystonia, though this practice is controversial
- Delirium management: Haloperidol remains widely used for delirium despite limited evidence of mortality benefit; lowest effective dose should be used for shortest duration; use is off-label
- TD monitoring: Screen for tardive dyskinesia regularly using the Abnormal Involuntary Movement Scale (AIMS); early detection and drug discontinuation may improve reversibility
- IV use: IV haloperidol is used off-label in ICU settings but has higher risk of QTc prolongation than oral/IM routes; requires cardiac monitoring
- Atypical antipsychotics: Second-generation (atypical) antipsychotics like risperidone and olanzapine have largely replaced haloperidol for chronic schizophrenia due to lower EPS rates
- Exam tip: If a question stem describes EPS (dystonia, akathisia, parkinsonism) after starting an antipsychotic, think high-potency typical agents like haloperidol
- NMS vs. serotonin syndrome: Both present with rigidity and hyperthermia, but NMS develops over days with "lead-pipe" rigidity and bradyreflexia, while serotonin syndrome develops over hours with hyperreflexia and clonus
High potency antipsychotics (Haloperidol, Fluphenazine, Trifluoperazine) = More EPS, Less "HAS" (Hypotension, Anticholinergic, Sedation). Low potency (Chlorpromazine, Thioridazine) = Less EPS, More "HAS".
Practice questions
1. A 28-year-old man is brought to the emergency department by police for bizarre behavior and paranoid delusions. He is agitated and threatening staff. After receiving intramuscular haloperidol, he develops sustained contraction of his neck muscles with his head turned to the left and upward deviation of his eyes. His vital signs are temperature 37.2°C, pulse 98/min, and blood pressure 132/84 mmHg. Which of the following is the most appropriate next step in management?
2. A 45-year-old woman with schizophrenia has been taking haloperidol for 18 months. She presents with involuntary movements of her mouth and tongue, including lip smacking and tongue protrusion. She is unaware of these movements. Her vital signs and physical examination are otherwise normal. Which of the following is the most likely diagnosis?
3. A 72-year-old man in the ICU with delirium receives intravenous haloperidol. Several hours later, he is found unresponsive. Telemetry shows polymorphic ventricular tachycardia. An ECG obtained just before the arrhythmia showed QTc of 580 ms. Which of the following best explains this patient's clinical deterioration?
Frequently asked questions
How does haloperidol work?
Haloperidol works by blocking dopamine D2 receptors in the brain. This reduces dopamine activity in the mesolimbic pathway, which decreases positive psychotic symptoms like hallucinations and delusions. The same D2 blockade in other brain pathways causes side effects: in the nigrostriatal pathway it produces extrapyramidal symptoms (muscle stiffness, tremor), and in the tuberoinfundibular pathway it raises prolactin levels causing galactorrhea and menstrual irregularities.
What are the side effects of haloperidol?
The most common side effects are extrapyramidal symptoms including acute dystonia (muscle spasms, twisted neck), parkinsonism (tremor, stiffness, slow movement), and akathisia (restlessness). Long-term use can cause tardive dyskinesia with involuntary facial and tongue movements that may be permanent. Other important effects include QTc prolongation with risk of dangerous heart rhythms, elevated prolactin causing breast discharge and sexual problems, and rarely neuroleptic malignant syndrome (fever, severe rigidity, confusion) which is a medical emergency.
Is haloperidol a controlled substance?
No, haloperidol is not a controlled substance. It does not have abuse potential and is not regulated under the Controlled Substances Act. However, it is a prescription medication that requires physician authorization and monitoring due to its significant side effects, particularly extrapyramidal symptoms and cardiovascular risks.
Haloperidol vs risperidone — what is the difference?
Haloperidol is a first-generation (typical) antipsychotic while risperidone is second-generation (atypical). The key difference is that haloperidol blocks mainly dopamine D2 receptors, causing high rates of extrapyramidal symptoms and tardive dyskinesia. Risperidone blocks both dopamine and serotonin (5-HT2A) receptors, which reduces the risk of movement side effects (though it still causes some EPS at higher doses). Risperidone causes more weight gain and metabolic effects than haloperidol, while haloperidol has greater risk of movement disorders.
What is haloperidol used to treat?
Haloperidol is FDA-approved for schizophrenia, Tourette syndrome, and severe behavioral problems in children. It is widely used off-label for acute psychosis, severe agitation requiring rapid tranquilization, delirium in hospitalized patients, and acute mania in bipolar disorder. It is also used off-label for managing chorea in Huntington disease, chemotherapy-induced nausea, and intractable hiccups when other treatments fail.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05AD01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.